

November 2025

Hikma is a global pharmaceutical company listed on the London Stock Exchange providing customers across North America, MENA and Europe with a broad range of generic, specialty and branded pharmaceutical products. In Algeria, Hikma is a leading provider of high-quality medicines serving healthcare professionals and patients across the country for over 30 years.



**Local expertise, global strength**

**4**  
Manufacturing plants

**860+**  
Colleagues

Hikma in Algeria is **ranked #3** among the pharmaceutical companies based on sales<sup>1</sup>

Hikma has a **6% market share** of the total Algerian pharmaceutical market<sup>1</sup>

Hikma was the **1<sup>st</sup>** to establish an oral **oncology manufacturing plant** in Algeria

**Making healthcare accessible for all**

We ensure our world-class medicines are within reach for all, improving access to healthcare in the country

**Manufacturing high-quality medicines**

**General formulation plant**  
Manufactures a variety of medicines in various dosage forms producing approximately 40 million units/year

**Penicillin plant**  
Manufactures approximately 20 million units/year of penicillin-based antibiotics

**Cephalosporin plant**  
Produces approximately 10 million units/year of high-quality anti-infectives commonly used to treat bacterial infections

**Oncology plant**  
First local oral oncology plant with the ability to produce various forms of oral oncology medicines

**A diversified portfolio of medicines**

We offer the Algerian patient over 114 medicines covering 8 therapeutic areas to address a wide range of healthcare needs:

Anti-infectives

Oncology

Respiratory

Cardiovascular

Diabetes

Gastrointestinal

Dermatology

Central Nervous System

Hikma was the **1<sup>st</sup>** multinational pharmaceutical company to register a **locally manufactured product** in Algeria

**Hikma is one of the leading providers of oral-systemic, oral anti-infectives**

**Launching an average of 5 new products in the market annually**

Reference:  
<sup>1</sup> Based on internal analysis by Hikma Pharmaceuticals PLC using data from the following source: IQVIA MIDAS® Quarterly value sales data for the countries listed below for the period: MAT Apr. 2025, Market definitions: Includes all therapeutic areas except for those ATC-3 classes that may encompass Nutrients, Infant Formulas, and Diagnostics elements within MIDAS Data, specifically ATCs SIT, T1G, T2X, T3A, V6C, and V6D, in each case reflecting estimates of real-world activity. Copyright IQVIA. All rights reserved.